Medical Bulletin 19/ November/ 2024 Dr. Bhumika Maikhuri19 Nov 2024 3:00 PM ISTHere are the top medical news for the day:NSAIDs Double Internal Bleeding Risk in Patients on AnticoagulantsPeople who take an anticoagulant medicine...
A Diabetes Drug May Maintain Kidney Health: Study Finds Dr. Bhumika Maikhuri19 Nov 2024 8:30 AM ISTType 2 diabetes can lead to diabetic kidney disease, but a class of drugs that cause the kidneys to remove glucose through urine has been gaining...
Dapagliflozin not better than metolazone at relieving congestion in HF patients with loop diuretic resistance Dr. Kamal Kant Kohli19 July 2023 9:15 AM ISTA recent study published in European Heart Journal showed a randomized trial comparing the sodium-glucose cotransporter 2 (SGLT2) inhibitor...
SGLT2 inhibitors improve total body composition except muscle mass in Type 2 diabetes patients Dr.Niharika Harsha B12 Jan 2023 7:30 PM ISTNew research found that SGLT-2 inhibitors revamp the body composition in T2DM by improving the body weight, body mass index, waist circumference,...
SGLT2 inhibitors not linked to increased bladder cancer risk: Study Jacinthlyn Sylvia19 Oct 2022 8:15 PM ISTA recent study by Devin Abrahami published in the journal of Diabetes Care found that sodium-glucose cotransporter 2 (SGLT2) inhibitors are not...
SGLT2I has an edge over DPP4I in lowering risk of NAFLD, and HCC among diabetes patients Dr.Niharika Harsha B5 Sept 2022 12:00 PM ISTSodium-glucose cotransporter 2 inhibitors (SGLT2I) have a low risk of non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC) in...
SGLT-2 inhibitors or GLP-1 receptor agonists use in type 2 diabetes: Expert Guidelines Medha Baranwal13 May 2021 7:00 PM ISTDelhi: An international panel including patients, clinicians, and methodologies has released risk-stratified recommendations concerning the use of...
Dapagliflozin Reduces Blood Pressure by Vasodilation, Finds Study MD Bureau25 March 2021 7:58 PM ISTHypertension and type 2 diabetes mellitus (T2DM) are risk factors for cardiovascular disease. Dapagliflozin improves both blood sugar and systolic...
Ertugliflozin Shows Better Renal Outcomes in diabetes patients with atherosclerotic CVD MD Bureau20 March 2021 12:03 AM ISTErtugliflozin is a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), is an approved glucose-lowering therapy in type 2 diabetes mellitus....
Canagliflozin has kidney-protective effects in patients with advanced kidney disease Dr Kartikeya Kohli20 Nov 2020 10:57 PM ISTWashington, DC - Researchers have found in Subgroup Analysis of the Randomized CREDENCE Trial, that the diabetes drug canagliflozin slowed kidney...
NEJM study confirms cardiac safety of Ertugliflozin in diabetes Dr Satabdi Saha25 Sept 2020 3:15 PM ISTAmong patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was non-inferior to placebo concerning major adverse...
SGLT2 Inhibitors tied to lower CV risk relative to DPP-4 Inhibitors in Diabetes: BMJ Dr. Kamal Kant Kohli24 Sept 2020 9:56 AM ISTPrevious trials have shown that SGLT2 inhibitors can reduce the risk of heart conditions such as heart attack, stroke, and heart failure compared with...
